Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on August 12, 2025, at 4:30 PM ET in Boston, MA.
The presentation will be accessible via live webcast and available for replay in the Investors section of biodesix.com under "News & Events".
Biodesix (NASDAQ:BDSX), azienda specializzata in soluzioni diagnostiche, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il CEO Scott Hutton e il CFO Robin Cowie parteciperanno a una conversazione informale e terranno incontri individuali con gli investitori il 12 agosto 2025 alle 16:30 ET a Boston, MA.
La presentazione sarà disponibile in diretta streaming e potrà essere rivista nella sezione Investitori di biodesix.com sotto la voce "News & Events".
Biodesix (NASDAQ:BDSX), una empresa de soluciones diagnósticas, anunció su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. El CEO Scott Hutton y el CFO Robin Cowie participarán en una charla informal y realizarán reuniones individuales con inversores el 12 de agosto de 2025 a las 4:30 PM ET en Boston, MA.
La presentación estará disponible vía webcast en vivo y podrá verse en repetición en la sección de Inversores de biodesix.com bajo "News & Events".
Biodesix (NASDAQ:BDSX)는 진단 솔루션 기업으로서 Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. CEO 스콧 허튼과 CFO 로빈 코위는 2025년 8월 12일 오후 4시 30분(동부시간)에 매사추세츠주 보스턴에서 열린 파이어사이드 채팅과 1:1 투자자 미팅에 참석할 예정입니다.
발표는 라이브 웹캐스트로 제공되며 biodesix.com의 투자자 섹션 내 "News & Events"에서 다시보기 가능합니다.
Biodesix (NASDAQ:BDSX), une entreprise de solutions diagnostiques, a annoncé sa participation à la 45e Conférence Annuelle de Croissance de Canaccord Genuity. Le PDG Scott Hutton et le CFO Robin Cowie participeront à une discussion informelle et tiendront des réunions individuelles avec des investisseurs le 12 août 2025 à 16h30 ET à Boston, MA.
La présentation sera accessible via une diffusion en direct et disponible en replay dans la section Investisseurs de biodesix.com sous "News & Events".
Biodesix (NASDAQ:BDSX), ein Unternehmen für diagnostische Lösungen, gab seine Teilnahme an der 45. jährlichen Wachstumskonferenz von Canaccord Genuity bekannt. CEO Scott Hutton und CFO Robin Cowie werden am 12. August 2025 um 16:30 Uhr ET in Boston, MA, an einem Fireside Chat teilnehmen und Einzelgespräche mit Investoren führen.
Die Präsentation wird per Live-Webcast verfügbar sein und kann im Bereich Investoren auf biodesix.com unter "News & Events" erneut angesehen werden.
- None.
- None.
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
Canaccord Genuity 45th Annual Growth Conference
Fireside Chat Date: Tuesday, August 12, 2025
Fireside Chat Time: 4:30 PM ET
Location: Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
Chris.Brinzey@icrhealthcare.com
1-339-970-2843
FAQ
When is Biodesix (BDSX) presenting at the Canaccord Genuity Growth Conference?
Who will represent Biodesix (BDSX) at the Canaccord Conference?
How can investors access Biodesix's Canaccord Conference presentation?
What type of meetings will Biodesix (BDSX) host at the Canaccord Conference?
